A Phase 2/3 interventional study of mRNA-1273 and Placebo in SARS-CoV-2, sponsored by ModernaTX, Inc.. Completed at 53 sites in 2 countries. Open to participants aged 12 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.
Sponsored by ModernaTX, Inc. (part of Moderna, Inc.) · Phase 2/3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 — 2 open to participants now, 5 under way, 1 of them phase 3. 2019-nCoV Vaccine mRNA-1273 · COVID-19.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, this one is the 6th largest by enrollment, is one of 4 that started in 2020, is one of 4 in phase 2/3, and was the 4th registered.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
Browse COVID-19 studies →2 of the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 are open now, in 1 country. Recruiting first, the newest first:
ModernaTX, Inc. · Sites in United States
Ages 12+ · Healthy volunteers
ModernaTX, Inc. · Sites in United States
Ages 6 mo+ · Healthy volunteers
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years to 18 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 14 · Phase 3 14 · Phase 4 7
First in 2020; this study’s year is marked. 4 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 4,328 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Median enrollment 499 across the 36 interventional studies. Of the 24 that completed or were terminated, 16 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
13 of 36 have an industry lead sponsor. The 10 most frequent:
This study is registered under ModernaTX, Inc., one of the names counted as Moderna, Inc.. Under that name alone:
ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
34 studies in COVID-19 by Moderna, Inc.: 3 open now, 6 under way, none of them phase 3. Of 28 finished, 11 (39%) have results posted.
Among the 34 studies in COVID-19 by Moderna, Inc., this one is the 6th largest by enrollment of the 22 interventional ones that give a count, is one of 4 that started in 2020, is one of 4 in phase 2/3, and was the 3rd registered.
Moderna, Inc.’s COVID-19 studies by the year they started, since 2020.
3 of the studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19 that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07863635ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Formulations | 2026-12-11 |
| NCT06585241ModernaTX, Inc.A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine Formulations | 2026-12-31 |
| NCT07266558ModernaTX, Inc.A Study to Evaluate the Efficacy and Safety of mRNA-1283 and mRNA-1273 in Participants 50 to 64 Years of Age Without High-Risk Conditions for Severe Coronavirus Disease 2019 (COVID-19) | 2027-06-16 |
Add all 3 to your calendar (.ics) → With an account.
Among the 36 studies testing 2019-nCoV Vaccine mRNA-1273 in COVID-19, from their registry updates:
Among Moderna, Inc.’s 34 in COVID-19:
This tab as a report to print or save as PDF → With an account.
The mRNA-1273 vaccine is being developed to prevent COVID-19, the disease resulting from Severe Acute Respiratory Syndrome coronavirus (SARS-CoV-2) infection. The study is designed to primarily evaluate the safety, reactogenicity, and effectiveness of mRNA-1273 vaccine administered as primary series and a booster dose (BD) to an adolescent population. The study will also evaluate the safety and immunogenicity of an mRNA-1273.222 vaccine against the SARS-CoV- 2 omicron variant as a primary series.
This is a Phase 2/3 study, with Part 1A (Blinded Phase), Part 1B (Open-label Observational Phase), Part 1C (Booster Dose [BD] Phase), which consists of Part 1C-1 and Part 1C-2, Part 2 (Open-Label), and Part 3 (Open-label). Participants in Part 1A are blinded to their treatment assignment, with participants receiving either 2 active mRNA-1273 vaccine doses or placebo. Part 1B of the study is designed to offer participants whose age group becomes Emergency Use Authorization (EUA) eligible to be unblinded so that participants who received placebo in Part 1A can request 2 doses of open-label mRNA-1273 vaccine. Part 1C-1 of the study will offer participants in Part 1A and Part 1B who are at least 5 months from the last dose, the option to request a homologous BD of mRNA-1273. Part 1C-2 is designed to provide a heterologous BD of mRNA-1273 to eligible participants who completed primary COVID-19 vaccination series with a non-Moderna vaccine under EUA and are at least 3 months from the last dose. Part 2 is an open-label design. Participants will receive 2 doses and may receive a booster dose of mRNA-1273 SARS-CoV-2 vaccine. Part 3 is an open-label design. Participants will receive up to 2 doses of mRNA-1273.222 vaccine.
Please access http://TeenCoveStudy.com for additional information, such as Study Overview, Participation, Site Locations along with contact numbers for each location for the study.
7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.
This study's enrollment of 4,328 is above the median of 102 across 4,367 interventional studies indexed under COVID-19.
Browse COVID-19 studies →ModernaTX, Inc. is the lead sponsor of 119 studies on the registry; 18 are open to participants now.
Of its 64 completed or terminated interventional studies of FDA-regulated products, 35 (55%) have results posted.
Compared within COVID-19, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Coronavirus Infections. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
For Part 1A, Part 2 and Part 3:
For Part 1B:
For Part 1C-1 Homologous Booster Dose:
Part 1C-2 Heterologous Booster Dose:
Exclusion Criteria:
For Part 1A, Part 2, and Part 3:
History of a diagnosis or condition that, in the judgment of the Investigator, may affect study endpoint assessment or compromise participant safety, specifically:
Receipt of:
For Part 1C-1 and Part 1C-2:
History of a diagnosis or condition (after enrolment in Part 1A) that, in the judgment of the investigator, may affect study endpoint assessment or compromise participant safety:
Receipt of:
Part 1C-2 Heterologous Booster Dose:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Part 1A (Blinded Phase): Participants will receive 2 intramuscular (IM) injections of mRNA-1273 (100 microgram \[ug\] each), 28 days apart, on Day 1 and Day 29. Part 1B (Open-Label Phase): Participants who cross over from placebo in Part 1A to Part 1B will receive 2 IM injections of mRNA-1273 (100 ug each), 28 days apart on Open Label Day 1 and Open Label Day 29. Part 2 (Open-Label): Participants will receive 2 IM injections of mRNA-1273 (50 ug each), 28 days apart, on Day 1 and Day 29 and may receive a booster dose on Day 149.
Biological: mRNA-1273
Part 1A (Blinded Phase): Participants will receive 2 IM injections of mRNA-1273 matching placebo, 28 days apart, on Day 1 and Day 29.
Biological: Placebo
Part 1C-1 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, 5 months after the last dose of Part 1A and 1B. Part 1C-2 (BD Phase): Participants will receive 1 IM injection of mRNA-1273 (50 ug) on BD-Day 1, at least 3 months post-last dose.
Biological: mRNA-1273
Part 3 (Open-Label): Participants will receive up to 2 IM injections of mRNA-1273.222 (50 ug each), 6 months apart, on Day 1 and Day 181.
Biological: mRNA-1273.222
Sterile liquid for injection
0.9% sodium chloride (normal saline) injection
Sterile solution for injection
Number of Participants With Solicited Local and Systemic Adverse Reactions (ARs)
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Solicited ARs considered causally related to injection were graded 1-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicated lower severity, and higher score indicated greater severity. Investigator reviewed if the solicited AR was recorded as an adverse event (AE) as detailed in the AE section. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the AE section.
Time frame: 7 days post-vaccination
Number of Participants With Unsolicited AEs
An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (onset after Day 7 of dosing). An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result or other safety assessment, including one that worsened from baseline and was considered clinically significant by the Investigator was recorded as an AE. Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were classified as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part1/2 but were considered clinical events for efficacy in Part 3 and not AEs. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the AE section.
Time frame: Up to 28 days post-vaccination
Part 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Pseudovirus nAb ID50 titers were measured using pseudovirus neutralization assay (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available (LLOQ: 18.5 arbitrary units (AU)/milliliter (mL), ULOQ: 45118 AU/mL). Antibody levels were analyzed using an analysis of covariance (ANCOVA) model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.
Time frame: Day 57 Study P203/Day 57 Study P301
Part 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Percentage of participants with seroresponse for pseudovirus nAb ID50 measured using PsVNA assay are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ (LLOQ: 18.5 AU/mL), ULOQ: 45118 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.
Time frame: Day 57 Study P203/Day 57 Study P301
Part 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Pseudovirus nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10, ULOQ: 281600). PPIS P301: randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
Time frame: BD Day 29 Study P203/Day 57 Study P301
Part 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above LLOQ (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
Time frame: BD Day 29 Study P203/Day 57 Study P301
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
Time frame: Day 29 Study P203/Day 57 Study P301
Part 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 29
Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
Time frame: BD Day 29
Part 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 57
Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
Time frame: Day 57
Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
Time frame: Day 29 Study P203/Day 57 Study P301
Part 2 SRR of Pseudovirus nAb Against Ancestral Strain
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above the LLOQ (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
Time frame: Day 57
Number of Participants With SAEs, AEs of Special Interest (AESIs), Medically Attended AEs (MAAEs), and AEs Leading to Study Discontinuation
SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. MAAE was an AE that led to an unscheduled visit to a healthcare practitioner, included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and visits to healthcare practitioners external to the study site \[for example, urgent care, primary care physician\]). Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were defined as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part 1/2 but were considered clinical events for efficacy in Part 3 and not AEs.
Time frame: Day 1 up to Day 751
Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic)
SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 status at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive postbaseline; or positive postbaseline.
Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection
Asymptomatic SARS-CoV-2 infection was defined as absence of symptoms and a positive RT-PCR or serology test (bAb levels against SARS-CoV-2 nucleocapsid protein) post dosing in participants who did not have an infection at baseline or pre-Dose 1.
Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19
COVID-19 was defined as symptomatic disease based on the following criteria: participants experienced at least 2 of the following systemic symptoms: fever (≥ 38ºC/≥ 100.4ºF), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and had at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2.
Time frame: Day 43 (14 days after second injection) up to 2.5 months after second injection
Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition)
Secondary case definition of COVID-19 was defined by the following criteria: 1 systemic or respiratory symptoms: fever (temperature \> 38ºC/≥ 100.4ºF), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea, and at least one positive test for SARS-CoV-2.
Time frame: Day 43 (14 days after second injection) up to a median follow up of 2.5 months after second injection
Part 1C-1 SRR of the Post-booster Serum Binding Antibody (bAb) Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD
Percentage of participants with seroresponse for bAb measured using (MesoScale Discovery) MSD are reported. Seroresponse from baseline (pre-Dose 1) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline (pre-Dose 1) is equal to or above the LLOQ.
Time frame: BD Day 29
Part 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529)
Post-booster Pseudovirus nAb against B.1.1.529 (LLOQ: 8 AU/mL, ULOQ: 24503 AU/mL). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available.
Time frame: BD Day 29
Part 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
Time frame: Day 29 Study P203/Day 57 Study P301
Part 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
Time frame: Day 29 P203/Day 57 P301
Part 3 GM Value of Post Dose 1 (Day 29) of mRNA-1273.222 bAb Against Other Variants of Interest
mRNA-1273.222 bAb was measured using a S-binding IgG immunoassay. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 397 AU/ml, ULOQ: 2200000 AU/mL).
Time frame: Day 29
Part 1C-2 GM Value of mRNA-1273 Booster Against Variants of Interest at Day 29
Time frame: Day 29
Part 1A GM Level of SARS-CoV-2 Spike Protein-specific bAb at Days 1, 57, 209, 394
SARS-CoV-2 Spike Protein-specific bAb were measured using MSD electrochemiluminescence multiplex assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 69 AU/mL, ULOQ: 14400000 AU/mL).
Time frame: Days 1, 57, 209, 394
Part 1A GM Value of SARS-CoV-2-Specific nAb at Days 1, 57, 209, 394
SARS-CoV-2-Specific nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL).
Time frame: Days 1, 57, 209, 394
Part 1C-1 GM Value of Post-booster Dose Serum bAb Against Variants of Interest (B.1.1.7, B.1.351, B.1.617.2, and P.1) as Measured by MSD
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. B.1.1.7 (LLOQ: 52, ULOQ: 8800000), B.1.351 (LLOQ: 111, ULOQ: 5000000), B.1.617.2 (LLOQ: 49, ULOQ: 7400000), P.1 (LLOQ: 143, ULOQ: 5800000).
Time frame: BD Day 29
Number of Deaths Related to Study Drug
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
Time frame: Day 1 up to Day 751
The study included Part 1A as the Blinded Phase with participants remaining blinded until the initiation of Part 1B (open-label cross-over vaccination phase), and Parts 1C-1, 1C-2, 2, and 3 as open-label.
| Milestone | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-2: mRNA-1273 50 μg Booster Dose (BD) | Part 2: mRNA-1273 50 μg | Part 3: mRNA-1273.222 50 µg |
|---|---|---|---|---|---|
| Started | 2490 | 1243 | 155 | 52 | 388 |
| Part 1: 1st injection | 2486 | 1240 | 0 | 0 | 0 |
| Part 1: 2nd injection | 2480 | 1222 | 0 | 0 | 0 |
| Part 2: 1st injection | 0 | 0 | 0 | 52 | 0 |
| Part 2: 2nd injection | 0 | 0 | 0 | 50 | 0 |
| Part 3: 1 dose | 0 | 0 | 0 | 0 | 388 |
| Part 3: 2 doses | 0 | 0 | 0 | 0 | 335 |
| Safety analysis set | 2486 | 1240 | 155 | 52 | 388 |
| Solicited safety set | 2485 | 1240 | 125 | 52 | 387 |
| Ppis | 340 | 0 | 136 | 46 | 373 |
| Per protocol (pp) set for efficacy | 2142 | 1044 | 0 | 0 | 0 |
| Part 2 bd | 0 | 0 | 0 | 19 | 0 |
| Ppis sars-cov-2 positive (ppis-pos) | 0 | 0 | 0 | 44 | 372 |
| Part 1c-1 bd | 1357 | 51 | 0 | 0 | 0 |
| Part 1b crossover vaccination | 0 | 96 | 0 | 0 | 0 |
| Part 1c-1 ppis-negative (neg) | 267 | 0 | 0 | 0 | 0 |
| Completed | 1274 | 74 | 143 | 41 | 358 |
| Not completed | 1216 | 1169 | 12 | 11 | 30 |
| Withdrew: Pregnancy | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Physician decision | 10 | 0 | 0 | 1 | 1 |
| Withdrew: Protocol deviation | 25 | 3 | 0 | 0 | 0 |
| Withdrew: Received another covid-19 vaccine under eua | 495 | 730 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 370 | 113 | 2 | 7 | 15 |
| Withdrew: Adverse event | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 256 | 29 | 10 | 3 | 6 |
| Withdrew: Other than specified | 59 | 294 | 0 | 0 | 4 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 1 |
Solicited ARs (local and systemic) were collected in an electronic diary (eDiary). Local ARs included injection site pain, injection site erythema (redness), injection site swelling/induration (hardness), and axillary (underarm) swelling or tenderness ipsilateral to the side of injection. Systemic ARs included fever, headache, fatigue, myalgia, arthralgia, nausea/vomiting, and chills. Solicited ARs considered causally related to injection were graded 1-4 (per Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials); lower score indicated lower severity, and higher score indicated greater severity. Investigator reviewed if the solicited AR was recorded as an adverse event (AE) as detailed in the AE section. A Summary of serious AEs (SAEs) and nonserious AEs ("Other"), regardless of causality, is located in the AE section.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg First Injection | Part 2: mRNA-1273 50 μg Second Injection | Part 2: mRNA-1273 50 μg BD | Part 3: mRNA-1273.222 50 μg 1 Dose |
|---|---|---|---|---|---|---|---|---|
| Grade 1 | 586 | 585 | 627 | 42 | 25 | 18 | 7 | 145 |
| Grade 2 | 1250 | 293 | 501 | 48 | 16 | 9 | 0 | 62 |
| Grade 3 | 627 | 59 | 150 | 9 | 1 | 3 | 1 | 25 |
| Grade 4 | 3 | 1 | 0 | 0 | 0 | 0 | 0 | 1 |
| Any Solicited (Grade 1-4) | 2466 | 938 | 1278 | 99 | 42 | 30 | 8 | 233 |
An unsolicited AE was any AE reported by the participant that was not specified as a solicited AR in the protocol or was specified as a solicited AR but started outside the protocol-defined period for reporting solicited ARs (onset after Day 7 of dosing). An AE was defined as any untoward medical occurrence associated with the use of a drug in humans, whether or not considered drug related. Any abnormal laboratory test result or other safety assessment, including one that worsened from baseline and was considered clinically significant by the Investigator was recorded as an AE. Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were classified as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part1/2 but were considered clinical events for efficacy in Part 3 and not AEs. A Summary of SAEs and nonserious AEs ("Other"), regardless of causality, is located in the AE section.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 2: mRNA-1273 50 μg BD | Part 3: mRNA-1273.222 50 μg 1 Dose |
|---|---|---|---|---|---|---|---|
| Number of Participants With Unsolicited AEs | 582 | 237 | 209 | 19 | 10 | 2 | 52 |
Pseudovirus nAb ID50 titers were measured using pseudovirus neutralization assay (PsVNA) assay. Antibody values reported as below the lower limit of quantification (LLOQ) were replaced by 0.5\*LLOQ. Values greater than the upper limit of quantification (ULOQ) were replaced by the ULOQ if actual values were not available (LLOQ: 18.5 arbitrary units (AU)/milliliter (mL), ULOQ: 45118 AU/mL). Antibody levels were analyzed using an analysis of covariance (ANCOVA) model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.
| titer | Part 1A: mRNA-1273 100 μg | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 1A Geometric Mean Value of Serum Pseudovirus Neutralizing Antibody (nAb) ID50 Titers From Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 1401.670 (1276.218 to 1539.453) | 1299.855 (1175.380 to 1437.511) |
Percentage of participants with seroresponse for pseudovirus nAb ID50 measured using PsVNA assay are reported. Seroresponse was defined as a change from below the LLOQ to equal above 4\*LLOQ, or at least a 4-fold rise if baseline is equal to or above the LLOQ (LLOQ: 18.5 AU/mL), ULOQ: 45118 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria were used for comparison assessments of immune response.
| percentage of participants | Part 1A: mRNA-1273 100 μg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg |
|---|---|---|
| Part 1A Seroresponse Rate (SRR) for Serum Pseudovirus nAb ID50 in Study P203 Vaccine Recipients at Day 57 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 98.8 (97.0 to 99.7) | 99.0 (97.1 to 99.8) |
Pseudovirus nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10, ULOQ: 281600). PPIS P301: randomly selected participants from study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
| arbitrary units (AU)/mL | Part 1C-1: mRNA-1273 50 µg BD | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 1C-1 Geometric Mean Concentration (GMC) of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 7102.0 (6553.2 to 7696.8) | 1400.4 (1272.7 to 1541.0) |
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above LLOQ (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
| percentage of participants | Part 1C-1: mRNA-1273 50 µg BD | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 1C-1 SRR of Serum Pseudovirus nAb Against the Original Strain After the BD in Study P203 at BD Day 29 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 100.0 (98.6 to 100.0) | 99.3 (97.6 to 99.9) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
| AU/mL | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 2727.8 (2558.7 to 2908.1) | 56.6 (52.7 to 60.8) |
Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
| AU/mL | Part 1C-2: mRNA-1273 50 μg BD |
|---|---|
| Part 1C-2 GMC of Post-booster Pseudovirus nAb Against Ancestral Strain at BD Day 29 | 9433.4 ± 8496.8 |
Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
| AU/mL | Part 2: mRNA-1273 50 μg |
|---|---|
| Part 2 GMC of the Pseudovirus nAb Against Ancestral Strain at Day 57 | 7351.5 ± 5621.7 |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL). ANCOVA model with the group variable (adolescents in P203 and young adults in P301) as fixed effect. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
| AU/mL | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 3 GMC of nAb Post Dose 1 mRNA 1273.222 Against SARS-CoV-2 Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 7603.9 (7004.6 to 8254.6) | 1692.3 (1543.4 to 1855.5) |
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse relative to pre-Dose 1 (baseline) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline was equal to or above the LLOQ (LLOQ: 10 AU/mL, ULOQ: 111433 AU/mL).
| percentage of participants | Part 2: mRNA-1273 50 μg |
|---|---|
| Part 2 SRR of Pseudovirus nAb Against Ancestral Strain | 91.3 ± 79.2 |
SAE was defined as any AE that resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in disability/permanent damage, was a congenital anomaly/birth defect, or was an important medical event. AESIs were identified based upon medical concepts that may be related to COVID-19 or were of interest in COVID-19 vaccine safety surveillance. MAAE was an AE that led to an unscheduled visit to a healthcare practitioner, included visits to a study site for unscheduled assessments (for example, abnormal laboratory follow-up, and visits to healthcare practitioners external to the study site \[for example, urgent care, primary care physician\]). Non-serious SARs persisting beyond 7 days, leading to discontinuation, or medically attended were defined as AEs in Part 1/2 but not in Part 3. COVID-19/SARS-CoV-2 infections were AEs in Part 1/2 but were considered clinical events for efficacy in Part 3 and not AEs.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1B: mRNA-1273 100 μg | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 2: mRNA-1273 50 μg BD | Part 3: mRNA-1273.222 50 μg |
|---|---|---|---|---|---|---|---|
| SAEs | 21 | 2 | 9 | 3 | 0 | 0 | 16 |
| AESIs | 17 | 0 | 9 | 1 | 0 | 0 | 3 |
| MAAEs | 1040 | 31 | 541 | 45 | 12 | 7 | 183 |
| AEs Leading to Study Discontinuation | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
SARS-CoV-2 infection was defined in participants with negative SARS-CoV-2 status at baseline: bAb level against SARS-CoV-2 nucleocapsid protein negative at Day 1, that became positive postbaseline; or positive postbaseline.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo |
|---|---|---|
| Part 1A Number of Participants With a SARS-CoV-2 Infection (Symptomatic or Asymptomatic) | 22 | 25 |
Asymptomatic SARS-CoV-2 infection was defined as absence of symptoms and a positive RT-PCR or serology test (bAb levels against SARS-CoV-2 nucleocapsid protein) post dosing in participants who did not have an infection at baseline or pre-Dose 1.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo |
|---|---|---|
| Part 1A Number of Participants With Asymptomatic SARS-CoV-2 Infection | 20 | 16 |
COVID-19 was defined as symptomatic disease based on the following criteria: participants experienced at least 2 of the following systemic symptoms: fever (≥ 38ºC/≥ 100.4ºF), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and had at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo |
|---|---|---|
| Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19 | 0 | 6 |
Secondary case definition of COVID-19 was defined by the following criteria: 1 systemic or respiratory symptoms: fever (temperature \> 38ºC/≥ 100.4ºF), or chills, cough, shortness of breath or difficulty breathing, fatigue, muscle aches, or body aches, headache, new loss of taste or smell, sore throat, congestion or runny nose, nausea, or vomiting or diarrhea, and at least one positive test for SARS-CoV-2.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo |
|---|---|---|
| Part 1A Number of Participants With Secondary Case Definition of COVID-19 (Center for Disease Control and Prevention [CDC] Case Definition) | 2 | 9 |
Percentage of participants with seroresponse for bAb measured using (MesoScale Discovery) MSD are reported. Seroresponse from baseline (pre-Dose 1) at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold-rise if baseline (pre-Dose 1) is equal to or above the LLOQ.
| Percentage of participants | Part 1C-1: mRNA-1273 50 µg BD |
|---|---|
| B.1.1.7 | 100.0 ± 98.9 |
| B.1.351 | 100.0 ± 98.9 |
| B.1.617.2 | 100.0 ± 98.9 |
| P.1 | 100.0 ± 98.9 |
Post-booster Pseudovirus nAb against B.1.1.529 (LLOQ: 8 AU/mL, ULOQ: 24503 AU/mL). Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available.
| AU/mL | Part 1C-1: mRNA-1273 50 µg BD |
|---|---|
| Part 1C-1 GMC of Post-booster Pseudovirus nAb Against Variant Strain (B.1.1.529) | 943.4 ± 853.5 |
Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ (LLOQ: 103 AU/mL, ULOQ: 28571 AU/mL). PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison of immune response.
| percentage of participants | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 3 SRR of Serum Pseudovirus nAb Post Dose 1 of mRNA-1273.222 Against Omicron BA.4/BA.5 Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 95.4 (92.8 to 97.3) | 0.0 (0.0 to 1.2) |
Percentage of participants with seroresponse for pseudovirus nAb measured using PsVNA assay are reported. Seroresponse from pre Dose 1 Baseline at a participant level was defined as a change from below the LLOQ to equal or above 4 \* LLOQ, or at least a 4-fold rise if Baseline was equal to or above the LLOQ. PPIS P301: randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria and SARS-CoV-2 negative were used for comparison assessments of immune response.
| percentage of participants | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427 ) mRNA-1273 100 μg |
|---|---|---|
| Part 3 Pseudovirus nAb SRR of Post Dose 1 of mRNA-1273.222 Against Ancestral Strain Compared With Those From Young Adult (18 to 25 Years of Age) Vaccine Recipients (Day 57) in Study P301 | 94.9 (92.1 to 96.9) | 99.3 (97.6 to 99.9) |
mRNA-1273.222 bAb was measured using a S-binding IgG immunoassay. Antibody values reported as below the LLOQ were replaced by 0.5 \* LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 397 AU/ml, ULOQ: 2200000 AU/mL).
| AU/mL | Part 3: mRNA-1273.222 50 µg |
|---|---|
| BA.5 | 282734.2 (266581.0 to 299866.1) |
| AY.4 | 557963.4 (529270.6 to 588211.6) |
| B.1.1.7 | 434879.0 (412699.2 to 458250.8) |
| B.1.351 | 431476.5 (409656.1 to 454459.1) |
| B.1.1.529 | 189826.0 (178578.0 to 201782.5) |
| P.1 | 471868.9 (446431.3 to 498756.0) |
No measurements were reported for this outcome.
SARS-CoV-2 Spike Protein-specific bAb were measured using MSD electrochemiluminescence multiplex assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 69 AU/mL, ULOQ: 14400000 AU/mL).
| AU/mL | Part 1A: mRNA-1273 100 μg |
|---|---|
| Day 1 | 65.848 (60.348 to 71.850) |
| Day 57 | 346830.736 (330758.387 to 363684.079) |
| Day 209 | 79624.290 (73959.321 to 85723.172) |
| Day 394 | 58647.246 (52309.921 to 65752.336) |
SARS-CoV-2-Specific nAb were measured using PsVNA assay. Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ are replaced by the ULOQ if actual values are not available (LLOQ: 10 AU/mL, ULOQ: 281600 AU/mL).
| AU/mL | Part 1A: mRNA-1273 100 μg |
|---|---|
| Day 1 | 11.249 (10.712 to 11.812) |
| Day 57 | 1868.363 (1758.809 to 1984.742) |
| Day 209 | 625.363 (583.319 to 670.437) |
| Day 394 | 550.262 (489.875 to 618.093) |
Antibody values reported as below the LLOQ were replaced by 0.5\*LLOQ. Values greater than the ULOQ were replaced by the ULOQ if actual values were not available. B.1.1.7 (LLOQ: 52, ULOQ: 8800000), B.1.351 (LLOQ: 111, ULOQ: 5000000), B.1.617.2 (LLOQ: 49, ULOQ: 7400000), P.1 (LLOQ: 143, ULOQ: 5800000).
| AU/mL | Part 1C-1: mRNA-1273 50 µg BD |
|---|---|
| B.1.1.7 | 581097.8 ± 543987.7 |
| B.1.351 | 431569.2 ± 404983.2 |
| B.1.617.2 | 456423.3 ± 429083.9 |
| P.1 | 417277.2 ± 391682.5 |
A death that occurred during the study or that came to the attention of the investigator during the study was reported to the Sponsor, whether or not it was considered related to study drug. The investigator assessed causality (that is, whether there is a reasonable possibility that the study drug caused the death). The relationship was characterized using the following classifications: Not related: There was not a reasonable possibility of a relationship to the study drug. The temporal sequence of the death relative to administration of the study drug was not reasonable and/or the death was more likely explained by a cause other than the study drug. Related: There was a reasonable possibility of a relationship to the study drug. There was evidence of exposure to the study drug. The temporal sequence of the death relative to the administration of the study drug was reasonable. The death was more likely explained by the study drug than by another cause.
| Participants | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1B: mRNA-1273 100 µg | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 2: mRNA-1273 50 μg BD | Part 3: mRNA-1273.222 50 μg 1 Dose | Part 3: mRNA-1273.222 50 ug Second Dose |
|---|---|---|---|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Deaths related to study drug | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Collected over Day 1 up to Day 751. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1A: mRNA-1273 100 μg | 0/2,486 (0%) | 21/2,486 (0.8%) | 943/2,486 (37.9%) |
| Part 1A: Placebo | 0/1,240 (0%) | 4/1,240 (0.3%) | 155/1,240 (12.5%) |
| Part 1B: mRNA-1273 100 µg | 0/96 (0%) | 2/96 (2.1%) | 22/96 (22.9%) |
| Part 1C-1: mRNA-1273 50 µg BD | 0/1,408 (0%) | 9/1,408 (0.6%) | 429/1,408 (30.5%) |
| Part 1C-2: mRNA-1273 50 μg BD | 0/155 (0%) | 3/155 (1.9%) | 28/155 (18.1%) |
| Part 2: mRNA-1273 50 μg | 0/52 (0%) | 0/52 (0%) | 12/52 (23.1%) |
| Part 2: mRNA-1273 50 ug BD | 0/19 (0%) | 0/19 (0%) | 7/19 (36.8%) |
| Part 3: mRNA1273.222 50 µg 1 Dose | 0/388 (0%) | 12/388 (3.1%) | 77/388 (19.8%) |
| Part 3: mRNA-1273.222 50 ug Second Dose | 1/335 (0.3%) | 4/335 (1.2%) | 51/335 (15.2%) |
| Event | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1B: mRNA-1273 100 µg | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 2: mRNA-1273 50 ug BD | Part 3: mRNA1273.222 50 µg 1 Dose | Part 3: mRNA-1273.222 50 ug Second Dose |
|---|---|---|---|---|---|---|---|---|---|
| Dengue feverInfections and infestations | 0/2486 | 0/1240 | 0/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 5/388 | 0/335 |
| Road traffic accidentInjury, poisoning and procedural complications | 0/2486 | 0/1240 | 1/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 0/335 |
| Suicidal ideationPsychiatric disorders | 5/2486 | 0/1240 | 1/96 | 2/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 0/335 |
| Anaphylactic reactionImmune system disorders | 0/2486 | 0/1240 | 0/96 | 0/1408 | 1/155 | 0/52 | 0/19 | 0/388 | 0/335 |
| SeizureNervous system disorders | 0/2486 | 0/1240 | 0/96 | 0/1408 | 1/155 | 0/52 | 0/19 | 0/388 | 0/335 |
| NephrolithiasisRenal and urinary disorders | 0/2486 | 0/1240 | 0/96 | 0/1408 | 1/155 | 0/52 | 0/19 | 0/388 | 0/335 |
| Abortion spontaneousPregnancy, puerperium and perinatal conditions | 0/2486 | 0/1240 | 0/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 2/335 |
| Normochromic normocytic anaemiaBlood and lymphatic system disorders | 0/2486 | 0/1240 | 0/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 1/335 |
| PeritonitisInfections and infestations | 0/2486 | 0/1240 | 0/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 1/335 |
| Gun shot woundInjury, poisoning and procedural complications | 0/2486 | 0/1240 | 0/96 | 0/1408 | 0/155 | 0/52 | 0/19 | 0/388 | 1/335 |
| Event | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1B: mRNA-1273 100 µg | Part 1C-1: mRNA-1273 50 µg BD | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 2: mRNA-1273 50 ug BD | Part 3: mRNA1273.222 50 µg 1 Dose | Part 3: mRNA-1273.222 50 ug Second Dose |
|---|---|---|---|---|---|---|---|---|---|
| COVID-19Infections and infestations | 382/2486 | 34/1240 | 11/96 | 257/1408 | 10/155 | 3/52 | 3/19 | 0/388 | 0/335 |
| InfluenzaInfections and infestations | 19/2486 | 0/1240 | 1/96 | 30/1408 | 7/155 | 1/52 | 2/19 | 5/388 | 0/335 |
| Upper respiratory tract infectionInfections and infestations | 257/2486 | 28/1240 | 3/96 | 81/1408 | 6/155 | 2/52 | 1/19 | 4/388 | 0/335 |
| NasopharyngitisInfections and infestations | 60/2486 | 6/1240 | 4/96 | 16/1408 | 0/155 | 0/52 | 0/19 | 30/388 | 23/335 |
| Respiratory tract infectionInfections and infestations | 11/2486 | 4/1240 | 0/96 | 2/1408 | 1/155 | 0/52 | 0/19 | 26/388 | 22/335 |
| Asymptomatic COVID-19Infections and infestations | 81/2486 | 25/1240 | 6/96 | 39/1408 | 2/155 | 2/52 | 0/19 | 0/388 | 0/335 |
| Attention deficit hyperactivity disorderPsychiatric disorders | 41/2486 | 6/1240 | 0/96 | 14/1408 | 2/155 | 3/52 | 0/19 | 0/388 | 0/335 |
| Injection site lymphadenopathyGeneral disorders | 137/2486 | 6/1240 | 0/96 | 5/1408 | 0/155 | 1/52 | 0/19 | 0/388 | 0/335 |
| Abdominal painGastrointestinal disorders | 8/2486 | 3/1240 | 0/96 | 6/1408 | 0/155 | 0/52 | 1/19 | 1/388 | 1/335 |
| Parainfluenzae virus infectionInfections and infestations | 3/2486 | 0/1240 | 1/96 | 2/1408 | 1/155 | 0/52 | 1/19 | 1/388 | 0/335 |
Part 1A Randomization Set: All participants who were randomized. Parts 1C-2, 2, and 3 Safety Set: participants who received at least 1 dose of study drug in Study mRNA-1273-P203 (P203). Study mRNA-1273-P301 (P301) (NCT04470427) mRNA-1273 100 μg: PPIS of randomly selected participants from Study P301 aged 18-25 meeting pre-specified criteria.
| Age, Customized(Participants) | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P203 — Adolescents (12-17 years) | 2490 | 1243 | 155 | 52 | 388 | 0 | 4328 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P203 — Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adolescents (12-17 years) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Age Categorical Data for Participants Enrolled in Study mRNA-1273-P301 — Adults (18-64 years) | 0 | 0 | 0 | 0 | 0 | 296 | 296 |
| Sex: Female, Male(Participants) | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|
| Sex Data for Participants Enrolled in Study mRNA-1273-P203 — Female | 1206 | 607 | 78 | 26 | 185 | 0 | 2102 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P203 — Male | 1284 | 636 | 77 | 26 | 203 | 0 | 2226 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Female | 0 | 0 | 0 | 0 | 0 | 153 | 153 |
| Sex Data for Participants Enrolled in Study mRNA-1273-P301 — Male | 0 | 0 | 0 | 0 | 0 | 143 | 143 |
| Ethnicity (NIH/OMB)(Participants) | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Hispanic or Latino | 280 | 152 | 37 | 14 | 367 | 0 | 850 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Not Hispanic or Latino | 2190 | 1079 | 116 | 36 | 21 | 0 | 3442 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P203 — Unknown or Not Reported | 20 | 12 | 2 | 2 | 0 | 0 | 36 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 78 | 78 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Not Hispanic or Latino | 0 | 0 | 0 | 0 | 0 | 216 | 216 |
| Ethnicity Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race/Ethnicity, Customized(Participants) | Part 1A: mRNA-1273 100 μg | Part 1A: Placebo | Part 1C-2: mRNA-1273 50 μg BD | Part 2: mRNA-1273 50 μg | Part 3: mRNA-1273.222 50 µg | Study mRNA-1273-P301 (NCT04470427) mRNA-1273 100 μg | Total |
|---|---|---|---|---|---|---|---|
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — White | 2087 | 1043 | 115 | 30 | 39 | 0 | 3314 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Black or African American | 83 | 42 | 23 | 18 | 126 | 0 | 292 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Asian | 143 | 80 | 3 | 3 | 0 | 0 | 229 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — American Indian or Alaska Native | 12 | 7 | 1 | 0 | 1 | 0 | 21 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Native Hawaiian or Other Pacific Islander | 3 | 0 | 0 | 0 | 0 | 0 | 3 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Multiple | 118 | 50 | 9 | 0 | 3 | 0 | 180 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Other | 27 | 9 | 4 | 0 | 219 | 0 | 259 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Not Reported | 11 | 11 | 0 | 0 | 0 | 0 | 22 |
| Race Data for Participants Enrolled in Study mRNA-1273-P203 — Unknown | 6 | 1 | 0 | 1 | 0 | 0 | 8 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — White | 0 | 0 | 0 | 0 | 0 | 207 | 207 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Black or African American | 0 | 0 | 0 | 0 | 0 | 29 | 29 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Asian | 0 | 0 | 0 | 0 | 0 | 30 | 30 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 2 | 2 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Multiple | 0 | 0 | 0 | 0 | 0 | 14 | 14 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Other | 0 | 0 | 0 | 0 | 0 | 8 | 8 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Not Reported | 0 | 0 | 0 | 0 | 0 | 3 | 3 |
| Race Data for Participants Enrolled in Study mRNA-1273-P301 — Unknown | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Dec 2020 to primary completion in Jun 2024, 42 months.
Results were first posted in Sep 2025, 1 year 3 months after primary completion.
Of 73 industry-sponsored phase 2/3 interventional studies under COVID-19, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 19. This study's 42 months is above that.
Counting every sponsor, half of 168 studies reached it within 11 months; a quarter within 5 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: 2019-nCoV Vaccine mRNA-1273 · Elasomeran/Davesomeran